Morgan Stanley maintains Universal Health Services stock rating

Published 04/06/2025, 11:08
Morgan Stanley maintains Universal Health Services stock rating

On Wednesday, Morgan Stanley (NYSE:MS) analysts reiterated an Equalweight rating on Universal Health Services (NYSE:UHS) stock, maintaining a price target of $200.00. The decision follows a virtual fireside chat with the company’s CFO, Steve Filton, as part of the firm’s ongoing C-Suite series of calls. The company, currently valued at $12.2 billion, has demonstrated strong financial performance with a 9.7% revenue growth over the last twelve months.

The discussion with Filton highlighted solid utilization trends in the acute business, with growth in the behavioral sector leaning more toward price adjustments. Morgan Stanley noted that Universal Health Services has underperformed compared to its peers, suggesting potential for a catchup trade. According to InvestingPro, the company maintains a "GREAT" overall financial health score, supported by strong profitability metrics and consistent dividend payments for 23 consecutive years.

Universal Health Services is trading toward the lower end of its valuation range, according to Morgan Stanley. The analysts pointed out that the stock’s performance relative to peers has been notably weaker, and policy impacts appear to be less severe, making the risk/reward scenario more appealing. The stock currently trades at an attractive P/E ratio of 10.2, and InvestingPro analysis suggests the stock is undervalued based on its Fair Value model.

Morgan Stanley’s analysts emphasized the importance of volume trends in the behavioral segment and policy outcomes for the company’s future performance. The firm continues to monitor these factors closely. Management has been actively returning value to shareholders through aggressive share buybacks, one of several positive indicators identified in InvestingPro’s comprehensive analysis of over 100 financial metrics.

For additional insights into Universal Health Services’ first-quarter earnings, Morgan Stanley referred to a previous report titled "Noisy print relative to peers; remain Equalweight."

In other recent news, Universal Health Services reported its first-quarter 2025 earnings, with earnings per share (EPS) of $4.80, exceeding the forecast of $4.36. The company, however, fell short on revenue, bringing in $4.1 billion compared to the anticipated $4.16 billion. Despite this, Universal Health Services maintained its full-year earnings guidance, indicating confidence in its financial outlook. In another development, the company declared a quarterly cash dividend of $0.20 per share, payable to shareholders on June 16, 2025. This move underscores its commitment to returning value to shareholders.

Cantor Fitzgerald recently reaffirmed a Neutral rating on Universal Health Services, maintaining a price target of $227.00. Analyst Sarah James noted staffing challenges in several cities but highlighted improvements in inpatient psychiatric care metrics. The company has not publicly responded to these observations. Investors are also keeping an eye on Universal Health Services’ ongoing efforts to manage operating expenses effectively, which contributed to a 21% increase in EBITDA for the quarter. These developments continue to shape investor perspectives on the company’s performance and strategic direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.